

**Igor Grant, M.D., F.R.C.P. (C)**  
**Distinguished Professor and Chair, UC San Diego, Department of Psychiatry**  
**Director, Center for Medicinal Cannabis Research**

Dr. Grant is a neuropsychiatrist whose research and clinical interests have focused on the effect of various diseases and drugs on the brain and behavior. He has been Principal Investigator of numerous Federal and Department of Veterans Affairs grants on this topic and has over 700 scientific publications to his credit. He is Director of the Translational Methamphetamine AIDS Research Center (TMARC) funded by the National Institute on Drug Abuse (NIDA). More detail can be found at Dr. Grant's website: <http://grant.hivresearch.ucsd.edu/>.

Since 2000, Dr. Grant has been Director of the State of California funded Center for Medicinal Cannabis Research (CMCR). The Center was funded following passage of California Prop 215, the "Compassionate Use Act" which envisioned providing patients under doctor supervision with access to medicinal cannabis in patients whose condition warranted it. California established the CMCR to develop a knowledge base concerning cannabis.

Headquartered at the University of California San Diego (UCSD), the Center has completed seven short term studies on medical cannabis in relation to neuropathic pain and muscle spasticity in Multiple Sclerosis. All the studies produced evidence of at least short term benefit of medicinal cannabis and these results have been published in the scientific literature and are available at: <http://www.cmcr.ucsd.edu/>.

Currently the CMCR is conducting a NIDA funded study comparing oral THC (dronabinol) to inhaled cannabis in pain management. Another study is examining the effects of cannabis on driving. Two additional studies have received funding and are under development. One is examining cannabinoids in bipolar disorder and the other will evaluate cannabis for treatment of HIV associated neuropathic pain. A fifth study is expected to be funded soon and will investigate the effectiveness of cannabidiol for the treatment of autism spectrum disorder.


CMCR has been the source of authoritative information that is developing on medicinal cannabis and has consulted with the Legislature of the State of California, the Office of the Lieutenant Governor of California (Blue Ribbon Commission's Regulatory & Tax Structure Working Group), and contributing to the recent National Academies report, "The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research" (2017).

# Medicinal Cannabis



Medical Board of California  
April 20, 2018

Igor Grant, M.D.,  
Director  
University of California, San Diego | Center for Medicinal Cannabis Research


UCSD UNIVERSITY OF CALIFORNIA, SAN DIEGO | WWW.CMCR.UCSD.EDU



## Cannabis and its derivatives



*Marijuana*




*Hashish*

Courtesy D. Piomelli, UCI


CMCR Center for Medicinal Cannabis Research | University of California, San Diego

## Cannabis: not a new medicine



## Main Events that Reawakened Interest in Medicinal Cannabis in the 1990s


- Persistent anecdotal reports of benefits
- Political shifts favoring medicinal access (in USA 23 states now provide for some measure of access)
- Discovery of the endocannabinoid system
  - » CB1 and CB2 receptors
  - » Anandamide (Devane, Mechoulam, et al Science 1992)
  - » 2-arachidonoylglycerol (2-AG: Sugiura, et al., Mechoulam et al., 1995), and other signaling molecules
  - » Development of synthetic molecules: agonists, partial agonists, antagonists, and other modifiers (eg., inhibitors of fatty acid amide hydrolase (FAAH). FAAH breaks down anandamide)




## Distribution of CB1 Receptors

Green shading indicates distribution of cannabinoid receptors in the body

- CNS
- Intestine
- Liver




## Distribution of CB1 Receptors



© CCIC TM 2010  
www.ccic.net

© CCIC TM 2010  
www.ccic.net

## The endogenous cannabinoids




Piomelli, *Nature Rev. Neurosci.*, 2003


### “Circuit Breaker” Function of CB Receptors

Neurotransmitter (eg., glutamate) action on post synaptic cells triggers them to release endocannabinoids (EC) that act on presynaptic CB receptors to regulate neurotransmission. The EC are then inactivated by FAAH or MGL\*

\* FAAH = fatty acid amide hydrolase    MGL = monoglyceride lipase (Courtesy D. Piomelli, UCI)


**Center for Medicinal Cannabis Research** | University of California, San Diego

## Marijuana Compounds



**+ 80 cannabinoids**


CC1=C(C(=O)OC2=CC(=CC=C2C1)O)C3=CC(=CC=C3)O

**Δ<sup>9</sup>-THC**  $C_{21}H_{35}O_2$


CC1=C(C(=O)OC2=CC(=CC=C2C1)O)C3=CC(=CC=C3)O

**CBD**  $C_{21}H_{34}O_2$

Isolation, structure and partial synthesis of an active constituent of hashish.  
 Y. Gaoni, Raphael Mechoulam. *J. Am. Chem. Soc.* 86, 1964: 1646.



Slide information courtesy of Dr. José Alexandre de Souza Crippa, Department of Neurosciences and Behavior, Ribeirão Preto Medical School, University of São Paulo, Brazil


**Center for Medicinal Cannabis Research** | University of California, San Diego



## Potential Medicinal Uses of Cannabis: NIH & IOM Reviews in late 90s

The NIH Workshop on the Medical Utility of Marijuana (1997) and the Institute of Medicine (1999), following thorough review, identified medical conditions warranting further research regarding the possible therapeutic effects of cannabis.

- Appetite Stimulation
- Nausea and Vomiting
- Analgesia
- Neurological and Movement Disorders



CMCR

Center for Medicinal Cannabis Research | University of California, San Diego

## University of California Center for Medicinal Cannabis Research (CMCR)

**Igor Grant, M.D.**

*Director*

J. Hampton Atkinson, MD & Tom Marcotte, PhD, Co-Directors

Barth Wilsey, MD, Ron Ellis, MD, PhD, Mark Wallace, MD, Robert Fitzgerald, PhD,  
Investigators; Ben Gouaux and Jennifer Marquie Beck, Senior Staff

[www.cmcrc.ucsd.edu](http://www.cmcrc.ucsd.edu)




CMCR

Center for Medicinal Cannabis Research | University of California, San Diego



## California Events Leading To CMCR

- November 1996:** California Prop 215 passes: Compassionate Use Act
- September 1999:** Medical Marijuana Research Act of 1999, authored by Senator John Vasconcellos (SB 847).
- August 2000:** Center for Medicinal Cannabis Research established at the University of California.
- September 2003:** Amendment to Medical Marijuana Research Act of 1999, sunset restrictions removed. (SB 295)

## CMCR Regulatory Pathway








### CMCR Clinical Studies completed


SITE	DISORDER	DESIGN	N	DOSE (% THC)	Result
UCSD Mark Wallace	Healthy Volunteers (Experimentally-Induced Pain)	Crossover RCT	15	0%, 2%, 4%, 8%	+
UCSF Donald Abrams	HIV Neuropathy, Experimental Pain	Parallel Groups RCT	50	0%, 3.5%	+
UCSD Ronald Ellis	HIV Neuropathy	Crossover RCT	28	0%, 1-8%	+
UCD Barth Wilsey	Neuropathic Pain, Experimental Pain	Crossover RCT	33	0%, 3.5%, 7%	+
UCD Barth Wilsey	Neuropathic Pain	Crossover RCT	39	0%, 1.29%, 3.53% (Vaporized)	+
UCSD Jody Corey- Bloom	MS Spasticity	Crossover RCT	30	0%, 4%	+
UCSD Mark Wallace	Diabetic Neuropathy	Crossover RCT	16	0%, 2%, 4%, 7%	+


**CMCR** Center for Medicinal Cannabis Research | University of California, San Diego


### How effective is cannabis relative to other pain medications? Number-Needed-to-Treat

- Number-Needed-to-Treat (NNT) = 1/Proportion improved in experimental condition – Proportion improved on placebo
- Ex: If 30% reduction in pain intensity = “Improved” and 60% “improve” in the experimental condition, while 30% “improve” in the placebo condition, then 0.60 – 0.30 = 0.30 and

**NNT = 1/.30 = 3.3**


**CMCR** Center for Medicinal Cannabis Research | University of California, San Diego

## Common Analgesics for Neuropathic Pain



*\*Number Needed to Treat to achieve a 30% reduction in pain.*


## Summary of CMCR Studies on Smoked Cannabis

- Data from CMCR placebo controlled, limited scale studies of smoked cannabis indicate positive response in neuropathic pain with effect sizes similar to other agents
- One CMCR study also found smoked cannabis reduced spasticity in MS patients
- Side effects were generally mild, with commonest being subjective high, fatigue, and tachycardia
- Neurocognitive testing revealed small reversible decrements during active treatment; comparable to effects of benzodiazepines, and antispasm, antiepileptic drugs for neuropathic pain and spasm
- Other side effects were sedation, dizziness, cough, throat irritation; all reversible and none necessitating discontinuation

## National Academies Report (2017) Evidence for Therapeutic Benefits of Cannabis


- **Substantial/conclusive evidence of cannabinoid efficacy in:**
  - » chronic pain
  - » Spasticity of multiple sclerosis
  - » Control of nausea
- **Moderate evidence of cannabinoid efficacy in :**
  - » Improving sleep in those with chronic medical conditions, eg., chronic pain, fibromyalgia etc.
- **Limited evidence of cannabinoid efficacy in**
  - » Treatment of certain anxiety disorders and PTSD
  - » Promoting appetite and weight gain
- **No or insufficient evidence of cannabinoid efficacy in**
  - » Treatment of cancers, irritable bowel syndrome, epilepsy, movement disorders due to Huntington Disease or Parkinson Disease, Schizophrenia

**Ref: The Health Effects of Cannabis and Cannabinoids.** Washington (DC): National Academies Press (US); 2017 Jan.

 **CMCR** Center for Medicinal Cannabis Research | University of California, San Diego

## Although it may be effective, smoked marijuana as medicine presents challenges



- » Safety of combustible material in clinical setting
- » Second hand smoke as an irritant, possibly health hazard
- » Efficiency and tolerability in smoking naïve
- » Availability of cigarettes with standardized dose
- » Conflict with anti drug laws
- » Possibility of misuse and diversion
- » Difficulty in conducting clinical trials on Schedule I substance whose legal availability is limited

 **CMCR** Center for Medicinal Cannabis Research | University of California, San Diego

## Plasma THC Levels – Smoked vs. Oral

inhaled cannabis ~34mg THC

15mg oral THC (dronabinol)



Mean plasma concentrations of  $\Delta^9$ -tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC) and 11-nor-9-carboxy-THC (THC-COOH) following administration smoked cannabis vs. oral dronabinol.

Source: Grotenhermen, et al. 2003. Clin Pharmacokinet 2003; 42 (4): 327-360.

## Devices for Marijuana Vaporization




E-cigarettes



Volcano®



Courtesy David Gorelick, MD



The Amazing BC VAPORIZER!

Your Healthy Alternative™

## Alternative Delivery Systems: “Volcano”

- Cannabis heated to 180° C
- Below the point of combustion (230° C)
- Releases cannabinoids as vapor into balloon
- Inhaled via mouthpiece attached to balloon




STORZ & BICKEL GMBH & CO. KG



CMCR Center for Medicinal Cannabis Research | University of California, San Diego

## CMCR Wilsey vaporizer study: Low dose THC containing cannabis reduces neuropathic pain



Placebo controlled randomized crossover study of 39 patients with neuropathic pain of mixed etiology treated 2x/d. THC conc. = 0%; 1.3%; 3.5%

Source: Wilsey, et al. Journal of Pain, 2013.

CMCR Center for Medicinal Cannabis Research | University of California, San Diego


## Nabiximols (Sativex®) oral mucosal spray

- Pump action oral mucosal spray
- Delivers 0.1 ml per spray of solution containing 25 mg/ml THC and 25 mg/ml CBD
- Derived from botanical sources, thus contains other cannabinoids and non cannabinoids (eg., flavonoids; terpenes)



Image courtesy G. Guy, GW Pharmaceuticals

## Nabiximols (Sativex®) for Neuropathic Pain



Reduction of global neuropathic pain NRS scores in the two groups during the trial. Weekly mean pain scores were obtained from pain diaries.


Source: Nurmikko, et al. (2007). Pain. 133; 210-220



## Current or potential cannabinoid modulators that may be administered orally

- Agonists
  - » Cannabis itself
  - » Synthetic THC (Dronabinol [Marinol] & analogs): Nabilone [Cesamet]; selective CB1 or CB2 agonists)
- Antagonists, partial agonists
  - » (Rimonabant, Taranabant, etc)
- Modifiers of endocannabinoid metabolism
  - » Fatty Acid Amide Hydrolase (FAAH) inhibitors; possibly monoglyceride lipase (MGL) inhibitors

## Other Cannabinoids: Cannabidiol



Terpene phenolic heterocyclic structures of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Red portions identify basic terpene (left) and phenol (right) backbones.

Cannabidiol actions do not seem to involve endocannabinoid system

No psychoactive effect

Filloux FM. Cannabinoids for pediatric epilepsy? Up in smoke or real science? *Transl Pediatr.* 2015 Oct;4(4):271-82.

## Cannabidiol - CBD

- Natural component of the Cannabis plant
- Constitutes up to 40% of marijuana extracts
- Devoid of typical psychological effects of THC
- Suggested applications as:
  - » Anti-inflammatory
  - » Analgesic
  - » Anti-emetic
  - » Hypnotic and sedative
  - » Antipsychotic
  - » Anticonvulsive
  - » Neuro-protective
  - » Anxiolytic
  - » Others
- Antagonism of THC when both contents are administered concomitantly? FAAH inhibition?

Slide information courtesy of Dr. José Alexandre de Souza Crippa, Department of Neurosciences and Behavior, Ribeirão Preto Medical School, University of São Paulo, Brazil


## Cannabidiol: Seizure Reduction in Epilepsy

STUDY	MODEL	EFFECT
<b>Human</b>		
Devinsky et al., 2015	N=137 children Dravet or Lennox Gastaud. Epidiolex, a CBD extract	+
Porter, et al. (2013)	N=19, children with treatment resistant epilepsy, survey results	+
Tremblay, et al. (1990)	N=12, 300mg cannabidiol/placebo	-
Ames, et al. (1985)	N=12, uncontrolled seizures, 200-300mg cannabidiol/placebo daily	-
Cunha, et al. (1980)	N=15, temporal lobe epilepsy, 200-300mg cannabidiol/placebo daily	+
Mechoulam, et al. (1978)	N=9, temporal lobe epilepsy, 200mg cannabidiol/placebo	+
<b>Pre-Clinical</b>		
Shirazi-zand, et al (2013)	Pentylenetetrazol, electroshock-induced seizures	+
Jones, et al (2012)	Intraventricular penicillin, pilocarpine-induced seizures	+
Jones, et al (2010)	Pentylenetetrazol-induced seizures, epileptiform activity in hippocampal tissue	+
Consroe, et al (1982)	Bicuculline, picrotoxin, 3-mercaptopropionic acid, pentylenetetrazol, isonicotinic acid hydrazide, electroshock induced seizures	+
Consroe, et al (1982)	Seizures induced by strychnine sulphate	-
Izquierdo, et al (1978)	Convulsant hippocampal discharges	+
Consroe, et al (1977)	Electroshock-induced seizure	+
Turkanis, et al (1974)	Electroshock-induced seizure	+
Carlini, et al (1973)	Leptazol-induced seizures	+

Sources: Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014 Mar 5;3:CD009270.  
 Dos Santos RG, et al. Phytocannabinoids and epilepsy. J Clin Pharm Ther. 2015 Apr;40(2):135-43. Devinsky O, Marsh E, Friedman D, et al Lancet Neurol. 2015;4422(15):1-9

## Cannabidiol (CBD) Significantly Reduces Drop Seizure Frequency in Lennox-Gastaut Syndrome (LGS)

Proportion of patients achieving 50% or greater reduction in episodes




Thiele AE et al. The American Epilepsy Society Annual Meeting; Houston, TX; December 2-6, 2016.

## Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients

Neuropsychopharmacology (2011), 1-8  
 © 2011 American College of Neuropsychopharmacology. All rights reserved 0893-133X/11 \$32.00

Mateus M Bergamaschi<sup>1,2,3</sup>, Regina Helena Costa Queiroz<sup>2,3</sup>, Marcos Hortes Nishihara Chagas<sup>1,3</sup>, Danielle Chaves Gomes de Oliveira<sup>1,3</sup>, Bruno Spinosa De Martinis<sup>3,4</sup>, Flávio Kapczinski<sup>3,5</sup>, João Quevedo<sup>3,6</sup>, Rafael Roesler<sup>3,7</sup>, Nadja Schröder<sup>3,8</sup>, Antonio E Nardi<sup>3,9</sup>, Rocio Martin-Santos<sup>3,10</sup>, Jaime Eduardo Cecilio Hallak<sup>1,3</sup>, Antonio Waldo Zuardi<sup>1,3</sup> and José Alexandre S Crippa<sup>1,3</sup>




Slide information courtesy of Dr. José Alexandre de Souza Crippa, Department of Neurosciences and Behavior, Ribeirão Preto Medical School, University of São Paulo, Brazil

## Role for cannabinoids in schizophrenia treatment? Some evidence for cannabinoid involvement

- Heavy MJ use associated with increased risk of psychosis in some studies; THC itself can produce acute psychosis
- PCP administration (animal model of psychosis) associated with regional brain increase in 2 AG
- Human PET studies show increase in CB1 binding in various brain regions in untreated schizophrenia
- Serum/CSF anandamide increased during onset of psychotic symptoms, but not in heavy MJ users
- Higher CSF anandamide associated with less likely transition to psychosis in “high risk” cases
- In psychosis cases treated with cannabidiol, improvement in negative symptoms associated with greater CSF anandamide rise


## Cannabidiol improves positive and negative symptoms of schizophrenia:

(42 cases randomized to receive 800 mg/d cannabidiol or amisulpride)



Leweke FM, Transl Psychiatry. 2012 Mar 20;2:e94.

Compared to atypical antipsychotic amisulpiride, cannabidiol does not worsen extrapyramidal symptoms, and is not associated with weight gain or elevated prolactin



Leweke FM, Transl Psychiatry. 2012 Mar 20;2:e94.

## Summary of current status of Medicinal Cannabis/Cannabinoid Modulators


- Smoked/vaporized cannabis, and extracts containing THC/CBD mix probably efficacious in neuropathic pain and spasticity from MS
- Possible efficacy in sleep disorders treatment
- Synthetic THC-like molecules efficacious in appetite stimulation and control of nausea
- Potential utility of other synthetic CB1 agonists not yet established
- CB1 antagonists, partial agonists may be useful in appetite suppression, but adverse psychiatric effects have been problematic
- Cannabidiol showing initial promise in treatment of anxiety, psychosis, and intractable epilepsy (eg., Dravet; Lennox Gastaud Syndromes)
- FAAH inhibitors promising in animal models of chronic pain
- Anti-inflammatory actions of cannabinoids deserve further exploration

## Medical Cannabis: Potential Public Health Benefits

- **Decreased opioid analgesic overdose deaths**
  - » Mean 25% decrease in states with medical cannabis (Bachhuber, et al., *JAMA Int Med*, 2014)
- **Decreased opioid analgesic misuse**
  - » Decreased treatment admissions for prescription opioid misuse
- **Decreased obesity**
  - » Associated with 2-6% decreased probability of obesity
- **Decreased alcohol use**
  - » Mixed findings

Courtesy David Gorelick, MD

## Association Between Medical Cannabis Laws & Opioid Analgesic Overdose Mortality in Each Year After Implementation of Laws in the US, 1999–2010



- Bachhuber MA et al. *JAMA Intern Med*. 2014 Oct;174(10):1668-73.

## Association Between Medical Cannabis Laws & State-Level Opioid Analgesic Overdose Mortality Rates in the US, 1999–2010

**Bachhuber MA et al.**  
JAMA Intern Med. 2014.

**Percentage Difference in Age-Adjusted Opioid Analgesic Overdose Mortality in States With vs Without a Law**

Independent Variable <sup>a</sup>	Primary Analysis	Secondary Analyses	
	Estimate (95% CI) <sup>b</sup>	Estimate (95% CI) <sup>c</sup>	Estimate (95% CI) <sup>d</sup>
Medical cannabis law	-24.8 (-37.5 to -9.5) <sup>e</sup>	-31.0 (-42.2 to -17.6) <sup>f</sup>	-23.1 (-37.1 to -5.9) <sup>e</sup>
Prescription drug monitoring program	3.7 (-12.7 to 23.3)	3.5 (-13.4 to 23.7)	7.7 (-11.0 to 30.3)
Law requiring or allowing pharmacists to request patient identification	5.0 (-10.4 to 23.1)	4.1 (-11.4 to 22.5)	2.3 (-15.4 to 23.7)
Increased state oversight of pain management clinics	-7.6 (-19.1 to 5.6)	-11.7 (-20.7 to -1.7) <sup>e</sup>	-3.9 (-21.7 to 18.0)
Annual state unemployment rate <sup>g</sup>	4.4 (-0.3 to 9.3)	5.2 (0.1 to 10.6) <sup>e</sup>	2.5 (-2.3 to 7.5)

<sup>a</sup>All models adjusted for state and year (fixed effects); <sup>b</sup>R<sup>2</sup> = 0.876; <sup>c</sup>All intentional (suicide) overdose deaths were excluded from the dependent variable; opioid analgesic overdose mortality is therefore deaths that are unintentional or of undetermined intent. All covariates were the same as in the primary analysis; R<sup>2</sup> = 0.873; <sup>d</sup>Findings include all heroin overdose deaths, even if no opioid analgesic was involved. All covariates were the same as in the primary analysis. R<sup>2</sup> = 0.842; <sup>e</sup>P ≤ .05; <sup>f</sup>P ≤ .001; <sup>g</sup>An association was calculated for a 1-percentage-point increase in the state unemployment rate.



RESEARCH  
EDUCATION  
TREATMENT  
ADVOCACY



PUBLISHED BY  
ELSEVIER

The Journal of Pain, Vol 17, No 6 (June), 2016; pp 739-744  
Available online at [www.jpain.org](http://www.jpain.org) and [www.sciencedirect.com](http://www.sciencedirect.com)

### Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain

Kevin F. Boehnke,<sup>\*</sup> Evangelos Litinas,<sup>†</sup> and Daniel J. Clauw<sup>1,§</sup>

MEDICATION TYPE	USE BEFORE INITIATION OF CANNABIS, N/N (%)	USE AFTER INITIATION OF CANNABIS, N/N (%)
Opioids	119/184 (65)	33/184 (18)
Nonsteroidal anti-inflammatory drugs	115/184 (62)	38/184 (21)
Disease-modifying antirheumatic drugs	15/184 (8)	3/184 (2)
Antidepressants	72/184 (39)	25/184 (14)
Serotonin–norepinephrine reuptake inhibitors	13/184 (7)	3/184 (2)
Selective serotonin reuptake inhibitors	34/184 (18)	8/184 (4)
Other	69/184 (38)	40/184 (22)

Courtesy Mark Ware, MD



**PRESCRIPTION DRUGS**

By Ashley C. Bradford and W. David Bradford

DOI: 10.1371/journal.pone.0205169  
HEALTH AFFAIRS 35,  
NO. 7 (2016): 1258-1268  
© 2016 Project HOPE—  
The People-to-People Health  
Foundation, Inc.

## Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D

**EXHIBIT 3**

Average numbers of daily doses filled for prescription drugs annually per physician in states with a medical marijuana law, by condition categories studied, compared to the average numbers in states without a law

Condition	Change in daily doses filled annually per physician
Anxiety	-562
Depression	-265
Glaucoma	35
Nausea	-541
Pain	-1,826
Psychosis	-519
Seizures	-486
Sleep disorders	-362
Spasticity	-32

**EXHIBIT 4**

Estimated annual change in national Medicare spending after implementation of state medical marijuana laws, by year

Year	Estimated change (\$)
2010	-104,513,189
2011	-114,995,271
2012	-130,491,985
2013	-165,193,681
2010-13	-515,194,125

Courtesy  
Mark  
Ware, MD

Center for Medicinal Cannabis Research | University of California, San Diego

## Medical Cannabis: Potential Public Health Harms

- Increased cannabis use
  - » Found in some, but not all, epidemiological analyses
- Increased incidence of cannabis use disorders
  - » Small increase in recent epidemiological analysis (Hasin et al., *JAMA Psychiatry*, 2017)
- Increased alcohol use
  - » Some evidence for both increased and decreased use (substitution)
- Increased cannabis-associated motor vehicle accidents
  - » Only in 3 states: CA, HI, WA (Masten & Guenzburger, *J Safety Res*, 2014)
- Increased unintended cannabis overdoses
  - » in Colorado, especially among children (e.g., Davis et al., *JAMA Psychiatry*, 2017)
- Increased crime around cannabis dispensaries
  - » Only in immediate vicinity (Long Beach, CA study)

Courtesy David Gorelick, MD

Center for Medicinal Cannabis Research | University of California, San Diego

## How do we move forward? In most countries, including the USA, it isn't that easy

- We need to separate out discourse on medicinal cannabis from that of broader social policy on recreational use [as we have done with other abusable drugs]
- We need both proof of principle and larger scale clinical trials on cannabis, administered via several routes, and specific constituents, plus their combinations. Consider effects of age, sex, comorbidities, other medications
- Tax dollars collected from cannabis sales can support such studies, which should also focus on longer term benefits, toxicity, and broader social effects.
- In the USA and other jurisdictions regulatory authorities need to “re-schedule” cannabis away from the most restrictive designation, recognizing that harm potential is modest, and there are medical benefits. This will facilitate medical research. Example: CBD, which is non psychoactive, is still Schedule 1 and practically unavailable for broader medical research
- In the USA the Federal Government needs to empower States to license producers for medical research to make available a diversity of products in a timely manner.
- If cannabis is to be used as a medicine, it needs to be capable of physician prescription, in accordance with agreed protocols, and subject to availability from trusted sources that confirm potency and purity, and regulated dispensing [eg., pharmacies; regulated dispensaries].

## Examples of future research directions on medicinal cannabis

- **Studies to address how patient diversity affects treatment response and vulnerability to adverse effects**
  - » Sex; Age; prior experience with cannabis; co-occurring conditions eg., psychiatric; non cannabis substance disorders; medical, eg., heart disease; liver disease
- **Studies on differential effectiveness, adverse effects, of various delivery systems**
  - » eg., smoked; other inhalational; oral; transdermal; oral-mucosal; suppositories
- **Studies on specific cannabinoids**
  - » ,eg., THC, CBD, their combination. Other cannabinoids and terpenes?
- **Studies on synergistic or sparing effects**
  - » Reduce or replace opioids, benzodiazepines, or other medications?
- **Studies on dosing:**
  - » eg., are therapeutic [such as analgesic] effects gained at lower doses than psychoactive? Effects of cannabinoid combinations

# Medicinal Cannabis

## Thank you!

**Igor Grant, M.D.**

*Director*

J. Hampton Atkinson, MD & Tom Marcotte, PhD, Co-Directors  
Barth Wilsey, MD, Ron Ellis, MD, PhD, Mark Wallace, MD, Robert Fitzgerald, PhD,  
Investigators; Ben Gouaux and Jennifer Marquie Beck, Senior Staff

[www.cmcrc.ucsd.edu](http://www.cmcrc.ucsd.edu)

